Insulet Corporation and GlaxoSmithKline Inc. Sign Distribution Agreement for the OmniPod® Insulin Management System in Canada
02 March 2011
Insulet's Tubing-free Insulin Pump to be Available across Canada for the First Time
BEDFORD, Mass., MISSISSAUGUA, Ont., (March 2, 2011) – Insulet Corporation ("Insulet" - Nasdaq: PODD), the leader in tubing-free insulin pump technology with its OmniPod® Insulin Management System, and GlaxoSmithKline Inc., one of the world's leading research-based pharmaceutical and healthcare companies, today announced an exclusive distribution agreement for the OmniPod® Insulin Management System in Canada.
"We are very pleased to work with a leader like GlaxoSmithKline Inc. to expand access to the OmniPod System to Canadians with diabetes," said Duane DeSisto, President and Chief Executive Officer of Insulet. "The OmniPod's tubing-free design and ease of use have provided freedom to tens of thousands of people in the United States and abroad. We look forward to the opportunity to positively impact the lives of Canadians with insulin-dependent diabetes."
"Partnering with Insulet to bring the OmniPod System to Canada directly reflects our mission to enable people to do more, feel better and live longer," said Paul Lucas, President and CEO, GlaxoSmithKline Inc. "As a patient-focused company with over a decade of experience in diabetes care, we are proud that the availability of this system will so significantly improve the management of diabetes for Canadian patients, their families and caregivers."
According to the agreement, GlaxoSmithKline Inc. will have exclusive rights to promote, advertise, market, distribute and sell the OmniPod® System in Canada. Additional information for Canadian patients and healthcare providers will soon be available at www.myomnipod.ca, which is currently scheduled to launch in mid-March 2011.
About the OmniPod® Insulin Management System
The OmniPod® Insulin Management System is the world's first tubing-free insulin pump. OmniPod® offers people living with insulin-requiring diabetes all the benefits of insulin pump therapy, with freedom, comfort and ease. OmniPod® has just two components: the small, discreet, waterproof Pod that can be worn on many parts of the body to hold and deliver insulin; and the PDM (Personal Diabetes Manager), a hand-held device that communicates wirelessly to program the Pod, calculates suggested doses and has a built-in FreeStyle(R) blood glucose meter. For more information, please visit: www.myomnipod.com (US residents only).
About Insulet Corporation
Insulet Corporation is an innovative medical device company dedicated to improving the lives of people with diabetes. The company's OmniPod® Insulin Management System is a revolutionary, discreet and easy-to-use insulin infusion system that features two easy-to-use parts with no tubing and fully-automated cannula insertion. Through the OmniPod® System, Insulet seeks to expand the use of continuous subcutaneous insulin infusion (CSII) therapy among people with insulin-dependent diabetes. Founded in 2000, Insulet Corporation is based in Bedford, Mass.
About GlaxoSmithKline Inc.
GlaxoSmithKline (GSK) is a leading research-based pharmaceutical company with a challenging and inspiring mission: to improve the quality of human life by enabling people to do more, feel better, and live longer. This mission gives GSK the purpose to develop innovative medicines, vaccines and healthcare solutions that help millions of people. GSK is consistently recognized as one of the 50 best employers in Canada and is a top 15 investor in Canadian research and development, contributing more than $144 million in 2009 alone. With a proud tradition of charitable and community support, GSK is designated a Caring Company by Imagine Canada. Discover more at GSK.ca.
Insulet Investor Relations:
Insulet Media Contacts: